Analysts have been eager to weigh in on the Healthcare sector with new ratings on Koninklijke Philips (PHG – Research Report), Doximity (DOCS – Research Report) and R1 RCM (RCM – Research Report).
Koninklijke Philips (PHG)
Koninklijke Philips received a Hold rating and a EUR19.50 price target from J.P. Morgan analyst David Adlington today. The company’s shares closed last Monday at $26.71.
According to TipRanks.com, Adlington is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Koninklijke Philips is a Hold with an average price target of $20.88.
See today’s best-performing stocks on TipRanks >>
Doximity (DOCS)
In a report released today, Anne Samuel from J.P. Morgan upgraded Doximity to Hold, with a price target of $25.00. The company’s shares closed last Monday at $24.27.
According to TipRanks.com, Samuel is a 4-star analyst with an average return of
Currently, the analyst consensus on Doximity is a Hold with an average price target of $29.82, a 24.3% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Hold rating on the stock with a $29.00 price target.
R1 RCM (RCM)
In a report released yesterday, Glen Santangelo from Jefferies maintained a Buy rating on R1 RCM, with a price target of $18.00. The company’s shares closed last Monday at $12.35.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of
Currently, the analyst consensus on R1 RCM is a Moderate Buy with an average price target of $16.64, representing a 35.3% upside. In a report issued on April 18, RBC Capital also maintained a Buy rating on the stock with a $19.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PHG:
- Philips (NYSE:PHG) Surges on Lower-than-Expected Settlement
- Philips to pay $1.1B in Respironics settlement
- Philips backs FY24 comparable sales view up 3%-5%
- Philips reports Q1 EPS EUR 0.21 vs. EUR 0.26 last year
- Philips delivers first-quarter results in line with 2024 performance improvement plan; Resolves the Respironics personal injury and medical monitoring litigation in the US for USD 1.1 billion
